Kappelin Johan, Ahnlide Ingela, Christensen Gustav B, Ingvar Åsa, Nielsen Kari
Lund University Skin Cancer Research Group, Department of Clinical Sciences Lund, Dermatology, Lund University, Sweden; Department of Dermatology, Skåne University Hospital, Landskrona, Sweden.
Lund University Skin Cancer Research Group, Department of Clinical Sciences Lund, Dermatology, Lund University, Sweden; Department of Dermatology, Skåne University Hospital, Lund, Sweden.
Acta Derm Venereol. 2025 Sep 23;105:adv42749. doi: 10.2340/actadv.v105.42749.
Hydrochlorothiazide has been associated with increased cutaneous squamous cell carcinoma risk. Meanwhile, its association with basal cell carcinoma (BCC) risk is controversial. The association between commonly prescribed antihypertensive medications and BCC risk in the Swedish population was investigated. All cases with a histopathologically verified BCC in Sweden during 2007-2017 and 2 matched controls per case were included in this nationwide, registry-based, case-control study. Information on prescribed anti-hypertensive drugs, comorbidities, co-medications, and socioeconomic factors was retrieved from nationwide registries. The odds of being treated with any of the chosen treatments in relation to BCC diagnosis were estimated. In total, 133,539 cases and 257,849 controls were studied. Thiazide-containing combination treatments (OR 1.09), angiotensin II receptor blockers (OR 1.09), calcium channel blockers (OR 1.09), and beta-blockers (OR 1.07) were associated with an increased BCC risk. Use of single-agent thiazide treat-ment did not affect BCC risk. In conclusion, statistically significant associations were found between several commonly prescribed antihypertensives and an increased BCC risk. Thiazide treatment affected BCC risk only when given as combination treatment, indicating that relevant adjunctive substances should be studied further in relation to BCC risk. Presently, it is suggested that prevention efforts focus on UV protection rather than altering antihypertensive treatments.
氢氯噻嗪与皮肤鳞状细胞癌风险增加有关。与此同时，它与基底细胞癌（BCC）风险的关联存在争议。本研究调查了瑞典人群中常用降压药与BCC风险之间的关联。这项基于全国登记处的病例对照研究纳入了2007年至2017年期间在瑞典所有经组织病理学证实为BCC的病例，以及每个病例匹配的2名对照。从全国登记处获取有关处方降压药、合并症、联合用药和社会经济因素的信息。估计了与BCC诊断相关的接受任何所选治疗的几率。总共研究了133,539例病例和257,849名对照。含噻嗪类的联合治疗（比值比1.09）、血管紧张素II受体阻滞剂（比值比1.09）、钙通道阻滞剂（比值比1.09）和β受体阻滞剂（比值比1.07）与BCC风险增加相关。使用单药噻嗪类治疗不影响BCC风险。总之，发现几种常用降压药与BCC风险增加之间存在统计学上的显著关联。噻嗪类治疗仅在作为联合治疗时影响BCC风险，这表明应进一步研究相关辅助物质与BCC风险的关系。目前，建议预防工作重点放在紫外线防护上，而不是改变降压治疗。
